Potential and novel therapies for asthma
Potential and novel therapies for asthma
Asthma is a chronic inflammatory disorder characterised by airflow obstruction. The inflammatory process involves mast cells, antigen presenting cells, eosinophils, neutrophils, airway epithelial cells and TH2 lymphocytes. These cells produce a broad array of pro-inflammatory mediators and cytokines that lead to the pathophysiological changes seen in asthma. The improved understanding of this complex disease, the specific cells and the complex mediators has lead to newer insights into the efficacy of various novel and potential therapies.
In this review, we discuss the pharmacological agents that interrupt the synthesis and action of leukotrienes, cytokine antagonism, monoclonal antibodies against IgEs, selective phosphodiesterase inhibitors, adenosine receptor ligands and immunomodulators to drive the inflammatory response towards a TH1 type and other possible specific targeted therapy for the management of asthma. Although most of these therapies are in the inchoate stages these may hold the future for use in asthma.
1096-1102
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
2000
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Babu, K.S. and Holgate, S.T.
(2000)
Potential and novel therapies for asthma.
The Journal of the Association of Physicians of India, 48 (11), .
Abstract
Asthma is a chronic inflammatory disorder characterised by airflow obstruction. The inflammatory process involves mast cells, antigen presenting cells, eosinophils, neutrophils, airway epithelial cells and TH2 lymphocytes. These cells produce a broad array of pro-inflammatory mediators and cytokines that lead to the pathophysiological changes seen in asthma. The improved understanding of this complex disease, the specific cells and the complex mediators has lead to newer insights into the efficacy of various novel and potential therapies.
In this review, we discuss the pharmacological agents that interrupt the synthesis and action of leukotrienes, cytokine antagonism, monoclonal antibodies against IgEs, selective phosphodiesterase inhibitors, adenosine receptor ligands and immunomodulators to drive the inflammatory response towards a TH1 type and other possible specific targeted therapy for the management of asthma. Although most of these therapies are in the inchoate stages these may hold the future for use in asthma.
This record has no associated files available for download.
More information
Published date: 2000
Identifiers
Local EPrints ID: 26914
URI: http://eprints.soton.ac.uk/id/eprint/26914
ISSN: 0004-5772
PURE UUID: d861cbf1-8907-4e41-b235-a36c673d4a1c
Catalogue record
Date deposited: 25 Apr 2006
Last modified: 08 Jan 2022 12:54
Export record
Contributors
Author:
K.S. Babu
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics